Skip to main content
Lunai Bioworks Inc. logo

Lunai Bioworks Inc. — Investor Relations & Filings

Ticker · RENB ISIN · US29350E1047 US Professional, scientific and technical activities
Open in API
Filings indexed 580 across all filing types
Latest filing 2016-11-14 Interim / Quarterly Rep…
Country US United States of America
Listing US RENB

About Lunai Bioworks Inc.

https://www.lunaibio.com

Lunai Bioworks Inc. is a pre-clinical stage biotechnology company that utilizes artificial intelligence for drug discovery and biodefense. The company focuses on pioneering safe and responsible generative biology to develop new therapies. By harnessing phenomics and AI, it aims to decode disease signals and translate them into treatments. Its proprietary Transformer Platform is designed to accelerate drug discovery processes. Lunai Bioworks develops medicines, diagnostics, and biodefense products, with a pipeline that includes programs for neurodegenerative conditions like Alzheimer's disease.

Recent filings

Filing Released Lang Actions
QUARTERLY REPORT
Interim / Quarterly Report Q1 2017
2016-11-14 English
AMENDMENT NO. 1 TO PRELIMINARY PROXY STATEMENT
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'AMENDMENT NO. 1 TO PRELIMINARY PROXY STATEMENT' and is filed as a Schedule 14A pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is a proxy statement for a special meeting in lieu of an annual meeting of stockholders, detailing proposals such as election of directors, charter amendments including a name change and reverse stock split, ratification of independent auditors, and adjournment of the meeting. The document includes detailed information about voting procedures, proposals, and corporate governance matters. This matches the definition of Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings. The document is not an Annual Report, Earnings Release, or Management Report, nor is it a simple announcement or certification. It is a full proxy statement with detailed voting information and proposals.
2016-11-10 English
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a letter from DanDrit Biotech USA, Inc. responding to comments from the SEC staff regarding their Preliminary Proxy Statement on Schedule 14A. The text discusses specific proposals related to a name change and reverse stock split, and addresses SEC comments on disclosure requirements under Schedule 14A. The document is clearly a correspondence related to a proxy solicitation filing, not the proxy statement itself. It is a regulatory correspondence responding to SEC comments on a proxy statement filing. Therefore, it is best classified under Regulatory Filings (RNS), as it does not contain the proxy statement itself or the actual solicitation materials, but rather a response to regulatory comments on such filings.
2016-11-10 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated November 9, 2016. It reports the entry into a material definitive agreement, specifically a Second Amendment to an Asset Purchase Agreement between Dandrit Biotech USA, Inc. and OncoSynergy Inc. The document includes a description of the amendment and references the original agreement. It does not contain financial statements or detailed financial data but rather announces a corporate transaction and amendment to a prior agreement. This type of filing is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a material contract amendment and does not fit into more specific categories like M&A filings or capital updates, as it is an amendment to an asset purchase agreement without merger or acquisition completion details. The document length is under 5,000 characters and is a standalone announcement, not a full report or financial statement.
2016-11-10 English
Regulatory Filings 2016
Regulatory Filings
2016-10-18 English
PRELIMINARY PROXY STATEMENT
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Preliminary Proxy Statement filed on Schedule 14A with the SEC, as indicated by the header and the text. It is related to a Special Meeting in Lieu of Annual Meeting of Stockholders for DanDrit Biotech USA, Inc. The document includes detailed information about proposals to be voted on, including election of directors, amendments to the company's charter, ratification of independent accountants, and adjournment of the meeting. It also contains instructions on voting and proxy procedures. This type of document is used to solicit shareholder votes and provide information necessary for shareholders to make informed decisions at the meeting. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length is substantial (15,000 characters), and it is the actual proxy statement, not just an announcement of its availability, so it is not a Report Publication Announcement (RPA).
2016-10-04 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.